M2U00315.MPG

(4:2)

M2U00315.MPG

(5:5)

M2U00315.MPG

(7)

M2U00315.MPG

(3:11)

M2U00315.MPG

(6:12)

M2U00315.MPG

(5)

M2U00315.MPG

(3:19)

M2U00315.MPG

(12)

M2U00315.MPG

(2:54)

Session 02/02, Comm.; 1- HBV to counsel about Tenofavir, 2- MND for PEG or RIG and for NIV

(1:22:1econd)

M2U00316.MPG

(8)

M2U00319.MPG

(2)

M2U00318.MPG

(24)

M2U00396.MPG

(47)

M2U01357

(19)

M2U00317.MPG

(3:55)

M2U00219.MPG

(21)

M2U00176.MPG

(1:55)

M2U00119.MPG

(49)

M2U00315.MPG

(18)

M2U00315.MPG

(1:40)

M2U00315.MPG

(15)

M2U00315.MPG

(2:50)

M2U00315.mpg

(1:1econd)

M2U00315.MPG

(49)

M2U00315.MPG

(1:5)

M2U00315.MPG

(2:37)

M2U00315.MPG

(20)

M2U00315.MPG

(25)

M2U00315.MPG

(1:49)